We suggest that the role of LRP5 as a regulator of HIF-1α stability under hypoxic conditions can be exploited as a novel therapeutic strategy targeting LRP5 for the treatment of myocardial infarction. This evidence concerns the gene HIF1A and myocardial infarction.